Drug Profile
Research programme: apolipoprotein E-mimetic peptide therapeutics - Cognosci Inc.
Alternative Names: COG 133; COG 241; COG 68Latest Information Update: 06 Jan 2020
Price :
$50
*
At a glance
- Originator Duke University
- Developer Cognosci
- Class Anti-inflammatories; Neuropeptides; Neuroprotectants; Small molecules
- Mechanism of Action Apolipoprotein E agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease; Brain injuries; Multiple sclerosis; Subarachnoid haemorrhage
Highest Development Phases
- Discontinued Alzheimer's disease; Inflammatory bowel diseases; Multiple sclerosis; Parkinson's disease; Rheumatoid arthritis
Most Recent Events
- 20 Aug 2019 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route) before August 2019 (Cognosci pipeline, August 2019)
- 20 Aug 2019 Discontinued - Preclinical for Multiple sclerosis in USA (unspecified route) before August 2019 (Cognosci pipeline, August 2019)
- 20 Aug 2019 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route) before August 2019 (Cognosci pipeline, August 2019)